Seer Inc. (SEER)
SEER trades on Nasdaq in Industrials, Biotechnology: Laboratory Analytical Instruments. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1726445/000119312526085481/0001193125-26-085481-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | SEER on Nasdaq |
| Sector | Industrials |
| Industry | Biotechnology: Laboratory Analytical Instruments |
| Country | United States |
| IPO year | 2020 |
| SEC CIK | 0001726445 |
| SEC industry code | Laboratory Analytical Instruments |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $16.6M |
| Net income | -$73.6M |
| Operating income | -$78.0M |
| Net margin | -444.0% |
| Operating margin | -470.5% |
| Revenue growth | +17.0% |
| Cash | $47.3M |
| Total assets | $296.1M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 5.0× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-10 |
| Cash and burn | $29.3M cash; operating cash flow -$11.3M a quarter. | Report 2026-09-30 |
| Shares outstanding | 55,814,767 (2026-11-06). | Cover page 2026-11-06 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Deloitte & Touche LLP, San Francisco, California, United States | PCAOB Form AP 2026-03-14 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $194K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $4.0M | -$13.7M | -$9.5M | $29.3M | No debt tags | $14.1M | 10-Q 2026-11-10 |
| Q2 2026 2026-06-30 | $3.1M | -$16.9M | -$9.6M | $26.1M | No debt tags | $14.2M | 10-Q 2026-08-11 |
| Q1 2026 2026-03-31 | $2.8M | -$16.8M | -$15.4M | $47.3M | No debt tags | $15.2M | 10-Q 2026-05-13 |
| Q4 2025 2025-12-31 | $4.2M | -$16.0M | -$10.8M | $47.3M | No debt tags | $16.6M | 10-K 2026-03-02 |
| Q3 2025 2025-09-30 | $4.1M | -$18.2M | -$7.6M | $45.0M | No debt tags | $16.4M | 10-Q 2026-11-10 |
| Q2 2025 2025-06-30 | $4.1M | -$19.4M | -$14.7M | $37.9M | No debt tags | $16.3M | 10-Q 2026-08-11 |
| Q1 2025 2025-03-31 | $4.2M | -$19.9M | -$11.4M | $52.4M | No debt tags | $15.3M | 10-Q 2026-05-13 |
| Q4 2024 2024-12-31 | $4.0M | -$21.7M | -$11.5M | $40.8M | No debt tags | $14.2M | 10-K 2026-03-02 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B4 | 2021-01-29 |
| Latest annual report | 10-K/A | 2026-04-30 |
| Latest quarterly / interim | 10-Q | 2026-11-10 |
| Latest current report | 8-K | 2026-11-10 |
| Latest proxy | DEFA14A | 2026-07-22 |
Source: SEC EDGAR submissions feed, 402 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -3.7% |
| 1 month | -25.6% |
| 3 months | -25.2% |
| Year to date | -14.2% |
| 1 year | -23.0% |
| From 52-week high | -32.6% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Laboratory Analytical Instruments
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| QTRX | Quanterix Corporation | $2.84 | -3.07% | $134.8M |
| HBIO | Harvard Bioscience Inc. | $8.91 | -5.96% | $40.7M |
| RPID | Rapid Micro Biosystems Inc. | $0.7400 | +13.67% | $37.1M |
| PRPO | Precipio Inc. | $19.96 | -9.81% | $35.8M |
| EYPT | EyePoint Inc. | $0.3076 | +0.52% | $35.0M |
| LAB | Standard BioTools Inc. | $0.6210 | -12.21% | $245.2M |
| NAUT | Nautilus Biotechnology Inc. | $2.10 | -9.48% | $267.5M |
| CIRC | Circle8 Group Inc. | $0.1702 | -7.30% | $20.0M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier